Your session is about to expire
← Back to Search
PBA for Color Blindness
Study Summary
This trial will study whether the drug glycerol phenylbutyrate can improve retinal function in patients with achromatopsia caused by ATF6 mutations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 80 Patients • NCT02117687Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any openings in this trial that new participants can join?
"At present, the trial is not taking on any new candidates. It was initially posted in January 1st of 2023 and most recently updated on 4th April 2022. If you are looking for alternative trials to participate in, 7 studies related to achromatopsia have open recruitment and 3 medical interventions targeting PBA are currently onboarding participants."
Is this the inaugural attempt at such a clinical trial?
"Presently, there are 3 ongoing studies regarding PBA that span 11 cities and 5 countries. The initial investigation into the drug was initiated in 2018 by Horizon Therapeutics, LLC as a Phase 4 drug approval trial with 18 patients contributing data. Since then, 12 more trials have been successfully concluded."
How many participants is the clinical trial currently seeking?
"This research is no longer recruiting participants; the trial's original posting on 1/1/2023 was last modified on 4/4/2022. For those looking for alternative studies, 7 achromatopsia trials and 3 PBA trials are now open to new patients."
Are there any precedential studies which have included PBA in their research?
"Currently, there are 3 studies involving PBA. Notably, none of these trials have reached Phase 3 status. These medical investigations are primarily located in Padua, Veneto but can also be found across 17 additional sites."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger